NCT02302989

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Leonard Feiner, MD, PhD · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration

Detailed description

This is an open-label, prospective, randomized study of intravitreally administered ranibizumab 0.5 mg in subjects with unilateral neovascular AMD in which the fellow (study) eye is at high-risk for also developing conversion to neovascular AMD. The Study will determine the efficacy of a quarterly injection of Ranibizumab to prevent the conversion of dry age-related macular degeneration to neovascular AMD in high risk eyes.

Conditions

• Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Ranibizumab 0.5mg

Timeline

• Start date: 2015-05-01
• Primary completion: 2018-07-01
• Completion: 2018-07-01
• First posted: 2014-11-27
• Last updated: 2018-08-28

Locations

2 sites across 1 country: United States